<div id="readability-page-1"><p>Gilman Hill Asset Management LLC lessened its holdings in shares of  Organon &amp; Co. (NYSE:OGN - Free Report) by 87.3% in the third quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 25,935 shares of the company's stock after selling 177,746 shares during the quarter. Gilman Hill Asset Management LLC's holdings in Organon &amp; Co. were worth $277,000 at the end of the most recent reporting period.</p><ul><li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li></ul><p>A number of other institutional investors have also added to or reduced their stakes in OGN. True North Advisors LLC purchased a new position in  Organon &amp; Co. during the 3rd quarter valued at about $158,000.  Douglas Lane &amp; Associates LLC grew its position in  Organon &amp; Co. by 40.5% during the third quarter. Douglas Lane &amp; Associates LLC now owns 443,876 shares of the company's stock worth $4,741,000 after buying an additional 127,924 shares in the last quarter.  GAMMA Investing LLC increased its stake in  Organon &amp; Co. by 22.4% in the 3rd quarter. GAMMA Investing LLC now owns 6,910 shares of the company's stock worth $74,000 after acquiring an additional 1,265 shares during the last quarter.  Osaic Holdings Inc. increased its stake in  Organon &amp; Co. by 25.5% in the 2nd quarter. Osaic Holdings Inc. now owns 60,791 shares of the company's stock worth $594,000 after acquiring an additional 12,363 shares during the last quarter.  Finally, Orion Porfolio Solutions LLC raised its holdings in shares of  Organon &amp; Co. by 96.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 63,509 shares of the company's stock valued at $615,000 after acquiring an additional 31,190 shares in the last quarter. Hedge funds and other institutional investors own  77.43% of the company's stock. </p><div><p><span></span><span>Get <strong>Organon &amp; Co.</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><p>A number of brokerages recently weighed in on OGN. JPMorgan Chase &amp; Co. decreased their price objective on Organon &amp; Co. from $14.00 to $12.00 and set an &#34;underweight&#34; rating on the stock in a report on Tuesday, November 11th. Barclays assumed coverage on shares of Organon &amp; Co. in a report on Tuesday, December 9th. They set an &#34;underweight&#34; rating and a $7.50 target price on the stock. Piper Sandler lowered shares of Organon &amp; Co. from an &#34;overweight&#34; rating to an &#34;underweight&#34; rating and set a $5.00 price target for the company. in a research report on Monday, October 27th. Morgan Stanley decreased their price objective on Organon &amp; Co. from $10.00 to $9.00 and set an &#34;equal weight&#34; rating on the stock in a report on Tuesday, November 11th. Finally, Weiss Ratings  restated a &#34;sell (d+)&#34; rating on shares of Organon &amp; Co. in a report on Wednesday, October 8th. One analyst  has rated the stock with a Strong Buy rating, two have assigned  a Hold rating and four have issued  a Sell rating to the company's stock. According to MarketBeat, the company  has an average rating of &#34;Reduce&#34; and a consensus target price of $8.38.</p><ul><li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li></ul><p><b>Get Our Latest Research Report on Organon &amp; Co.</b></p><h2>Organon &amp; Co. Trading Up 0.1%</h2><p>OGN opened at $7.10 on Thursday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 3.70, a PEG ratio of 1.52 and a beta of 0.57. Organon &amp; Co. has a one year low of $6.18 and a one year high of $17.23. The business has a 50 day simple moving average of $7.44 and a two-hundred day simple moving average of $9.03. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20. </p><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.08. Organon &amp; Co. had a return on equity of 143.47% and a net margin of 7.95%.The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the company earned $1.38 earnings per share.  Analysts predict that  Organon &amp; Co. will post 3.68 EPS for the current year. </p><h2>Organon &amp; Co. Dividend Announcement</h2><p>The company also recently announced a quarterly dividend, which was paid on Thursday, December 11th. Shareholders of record on Thursday, November 20th were issued a dividend of $0.02 per share. The ex-dividend date was Thursday, November 20th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.1%. Organon &amp; Co.'s dividend payout ratio  is 4.17%. </p><h2>About Organon &amp; Co.</h2> (Free Report)<p>Organon &amp; Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck &amp; Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact. </p><p>In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.</p><h2>See Also</h2><ul><li>Five stocks we like better than Organon &amp; Co.</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><strong>Want to see what other hedge funds are holding OGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon &amp; Co. (NYSE:OGN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2><p>Before you consider Organon &amp; Co., you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p><p>While Organon &amp; Co. currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Gilman Hill Asset Management LLC reduced its holdings in Organon & Co. by 87.3% in Q3, owning 25,935 shares worth $277,000. Other investors adjusted their stakes, with mixed analyst ratings on OGN. The stock opened at $7.10, with a market cap of $1.84 billion. Organon reported Q3 earnings of $1.01 per share, beating estimates, and announced a $0.02 dividend.</p>

Gilman Hill Asset Management LLC Reduces Position in Organon & Co. $OGN